-- Orthocell (ASX:OCC) said it achieved a revenue of AU$3.2 million in the March quarter, in line with the prior quarter and primarily driven by sales of its nerve repair product, Remplir, according to a Monday Australian bourse filing.
The company expects a material uplift in US revenue in the upcoming quarters after the establishment of a commercial distribution platform in the country, with its network expanded to cover over 16 states and around 40% of the population.
Regulatory approval for the commercial distribution of Remplir in the US and UK is anticipated in the second half of 2026.
Orthocell's shares fell past 5% in recent trading on Monday.